Get started
Author

Andrew Chantry

Observed names: A Chantry, A. Chantry, A. D. Chantry, A.D. Chantry, ANDREW CHANTRY, Andrew D Chantry, Andrew D. Chantry, Andrew Douglas Chantry, Andrew. D. Chantry, Andy Chantry, Chantry, A, Chantry, Andrew D.
Observed institutions: National Health Service, Royal Hallamshire Hospital, Multiple Sclerosis Society, University of Oxford, Sheffield Teaching Hospitals NHS Foundation Trust, Insigneo, MRC Lifecourse Epidemiology Unit, Alfred Health, University of Southampton, UCL Queen Square Institute of Neurology, Imperial College London, Monash University, Sheffield Hallam University, University of Sheffield
ORCID: 0000-0002-2797-7626
Observed ORCID: 0000-0002-2797-7626
OpenAlex ID: A5071841663
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
2019 · Paul G Richardson, Albert Oriol, et al. · The Lancet Oncology · 384
Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma
2008 · Deborah J Heath, Andrew D Chantry, et al. · Journal of Bone and Mineral Research · 251
PDF
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
2018 · Meletios A Dimopoulos, Francesca Gay, et al. · The Lancet · 237
PDF
Bortezomib reduces serum dickkopf‐1 and receptor activator of nuclear factor‐κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
2006 · Evangelos Terpos, Deborah J. Heath, et al. · British Journal of Haematology · 221
PDF
Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo
2010 · Andrew D Chantry, Debby Heath, et al. · Journal of Bone and Mineral Research · 147
PDF
Guidelines for the use of imaging in the management of patients with myeloma
2017 · Andrew Chantry, Majid Kazmi, et al. · British Journal of Haematology · 131
PDF
The Kinase Domain and Membrane Localization Determine Intracellular Interactions between Epidermal Growth Factor Receptors
1995 · Andrew Chantry · Journal of Biological Chemistry · 74
Myeloma bone disease: pathogenesis, current treatments and future targets
2014 · R. E. Walker, M. A. Lawson, et al. · British Medical Bulletin · 67
ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation
2020 · Dan Zhang, Kim De Veirman, et al. · Stem Cell Research & Therapy · 47
PDF
Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience
2020 · Lewis Kass-Iliyya, John A. Snowden, et al. · Journal of Neurology · 47
PDF
New agents in the Treatment of Myeloma Bone Disease
2017 · Elizabeth S. Ring, Michelle A. Lawson, et al. · Calcified Tissue International · 44
PDF
A systems biology approach to Down syndrome: Identification of Notch/Wnt dysregulation in a model of stem cells aging
2009 · C.J. Cairney, G. Sanguinetti, et al. · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 42
NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease
2015 · Michelle A. Lawson, Julia M. Paton-Hough, et al. · PLoS ONE · 41
PDF
A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells.
1996 · J M Coulson, D R Poyner, et al. · Molecular Pharmacology · 39
A Small Molecule Modulator of Prion Protein Increases Human Mesenchymal Stem Cell Lifespan, Ex Vivo Expansion, and Engraftment to Bone Marrow in NOD/SCID Mice
2012 · Sindhu T. Mohanty, Claire J. Cairney, et al. · Stem Cells · 38
PDF
A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease
2015 · J. Paton-Hough, A.D. Chantry, et al. · Bone · 37
Multiple myeloma—A painful disease of the bone marrow
2020 · Marta Diaz-delCastillo, Andrew D. Chantry, et al. · Seminars in Cell and Developmental Biology · 36
Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models
2018 · Julia Paton-Hough, Simon Tazzyman, et al. · Journal of Bone and Mineral Research · 34
PDF
The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma
2020 · Lisa J. Crawford, David C. Campbell, et al. · Oncogene · 32
PDF
Myeloma impairs mature osteoblast function but causes early expansion of osteo‐progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model
2015 · Deepika Kassen, Darren Lath, et al. · British Journal of Haematology · 28
PDF
Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma
2023 · Rong Fan, Hatice Satilmis, et al. · Journal for ImmunoTherapy of Cancer · 27
PDF
The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate)
2017 · Michelle A Lawson, Frank H Ebetino, et al. · Journal of Bone and Mineral Research · 27
PDF
Overexpression of ErbB2 impairs ligand-dependent downregulation of epidermal growth factor receptors via a post-transcriptional mechanism
1999 · Guocai Huang, Andrew Chantry, et al. · Journal of Cellular Biochemistry · 26
TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model
2019 · Alanna C Green, Darren Lath, et al. · Journal of Bone and Mineral Research · 24
PDF
Mechanisms and treatment of bone pain in multiple myeloma
2019 · Matthew Philip Davies, Sam Fingas, et al. · Current Opinion in Supportive and Palliative Care · 23
Works count: 97
Citation count: 2,561
H-index: 24
I10-index: 44
Year
Topic
Type